Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/13800
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pingaew R. | |
dc.contributor.author | Saekee A. | |
dc.contributor.author | Mandi P. | |
dc.contributor.author | Nantasenamat C. | |
dc.contributor.author | Prachayasittikul S. | |
dc.contributor.author | Ruchirawat S. | |
dc.contributor.author | Prachayasittikul V. | |
dc.date.accessioned | 2021-04-05T03:32:26Z | - |
dc.date.available | 2021-04-05T03:32:26Z | - |
dc.date.issued | 2014 | |
dc.identifier.issn | 2235234 | |
dc.identifier.other | 2-s2.0-84905161366 | |
dc.identifier.uri | https://ir.swu.ac.th/jspui/handle/123456789/13800 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905161366&doi=10.1016%2fj.ejmech.2014.07.087&partnerID=40&md5=4c490e6ea3dea932430f55e04459096e | |
dc.description.abstract | A new series of chalcone-coumarin derivatives (9-19) linked by the 1,2,3-triazole ring were synthesized through the azide/alkyne dipolar cycloaddition. Hybrid molecules were evaluated for their cytotoxic activity against four cancer cell lines (e.g., HuCCA-1, HepG2, A549 and MOLT-3) and antimalarial activity toward Plasmodium falciparum. Most of the synthesized hybrids, except for analogs 10 and 16, displayed cytotoxicity against MOLT-3 cell line without affecting normal cells. Analogs (10, 11, 16 and 18) exhibited higher inhibitory efficacy than the control drug, etoposide, in HepG2 cells. Significantly, the high cytotoxic potency of the hybrid 11 was shown to be non-toxic to normal cells. Interestingly, the chalcone-coumarin 18 was the most potent antimalarial compound affording IC50 value of 1.60 μM. Molecular docking suggested that the cytotoxicity of reported hybrids could be possibly due to their dual inhibition of α- and β-tubulins at GTP and colchicine binding sites, respectively. Furthermore, falcipain-2 was identified to be a plausible target site of the hybrids given their antimalarial potency. © 2014 Elsevier Masson SAS. All rights reserved. | |
dc.subject | 4 ((1 (3 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 4 ((1 (3 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 4 ((1 (3 (3 (3,4 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 4 ((1 (4 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 4 ((1 (4 (3 (3,4,5 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yll)methoxy) 2h chromen 2 one | |
dc.subject | 7 ((1 (3 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 7 ((1 (3 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 7 ((1 (3 (3 (3,4 dimethoxyphenyl)acryloyl)phenyl) 1 h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 7 ((1 (4 (3 (2,3 dimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 7 ((1 (4 (3 (2,3,4 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | 7 ((1 (4 (3 (3,4,5 trimethoxyphenyl)acryloyl)phenyl) 1h 1,2,3 triazol 4 yl)methoxy) 2h chromen 2 one | |
dc.subject | alpha tubulin | |
dc.subject | antimalarial agent | |
dc.subject | antineoplastic agent | |
dc.subject | beta tubulin | |
dc.subject | chalcone derivative | |
dc.subject | coumarin derivative | |
dc.subject | etoposide | |
dc.subject | falcipain 2 | |
dc.subject | unclassified drug | |
dc.subject | 1,2,3 triazole derivative | |
dc.subject | 4 [[1 [3 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 4 [[1 [3 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 4 [[1 [3 [3 (3,4 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 4 [[1 [4 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 4 [[1 [4 [3 (3,4,5 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 7 [[1 [3 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 7 [[1 [3 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 7 [[1 [3 [3 (3,4 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 7 [[1 [4 [3 (2,3 dimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 7 [[1 [4 [3 (2,3,4 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | 7 [[1 [4 [3 (3,4,5 trimethoxyphenyl)acryloyl]phenyl] 1h 1,2,3 triazol 4 yl]methoxy] 2h chromen 2 one | |
dc.subject | antimalarial agent | |
dc.subject | antineoplastic agent | |
dc.subject | chalcone derivative | |
dc.subject | colchicine | |
dc.subject | coumarin derivative | |
dc.subject | dihydroartemisinin | |
dc.subject | doxorubicin | |
dc.subject | ellipticine | |
dc.subject | etoposide | |
dc.subject | falcipain 2 | |
dc.subject | n [n (3 carboxyoxirane 2 carbonyl)leucyl]agmatine | |
dc.subject | tubulin | |
dc.subject | antimalarial agent | |
dc.subject | antineoplastic agent | |
dc.subject | chalcone | |
dc.subject | coumarin | |
dc.subject | coumarin derivative | |
dc.subject | cysteine proteinase | |
dc.subject | triazole derivative | |
dc.subject | antimalarial activity | |
dc.subject | antineoplastic activity | |
dc.subject | article | |
dc.subject | cancer cell line | |
dc.subject | carbon nuclear magnetic resonance | |
dc.subject | cycloaddition | |
dc.subject | cytotoxicity | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | HepG2 cell line | |
dc.subject | human | |
dc.subject | human cell | |
dc.subject | molecular docking | |
dc.subject | Plasmodium falciparum | |
dc.subject | proton nuclear magnetic resonance | |
dc.subject | A549 cell line | |
dc.subject | AGMK cell line | |
dc.subject | animal cell | |
dc.subject | antimalarial activity | |
dc.subject | Article | |
dc.subject | cholangiocarcinoma cell line | |
dc.subject | controlled study | |
dc.subject | crystal structure | |
dc.subject | drug binding site | |
dc.subject | drug cytotoxicity | |
dc.subject | drug potency | |
dc.subject | drug screening | |
dc.subject | drug synthesis | |
dc.subject | hydrogen bond | |
dc.subject | IC50 | |
dc.subject | leukemia cell line | |
dc.subject | lymphatic leukemia | |
dc.subject | molecular docking | |
dc.subject | nonhuman | |
dc.subject | structure activity relation | |
dc.subject | Vero cell line | |
dc.subject | chemistry | |
dc.subject | drug effects | |
dc.subject | metabolism | |
dc.subject | protein conformation | |
dc.subject | synthesis | |
dc.subject | tumor cell line | |
dc.subject | Antimalarials | |
dc.subject | Antineoplastic Agents | |
dc.subject | Cell Line, Tumor | |
dc.subject | Chalcone | |
dc.subject | Chemistry Techniques, Synthetic | |
dc.subject | Coumarins | |
dc.subject | Cysteine Endopeptidases | |
dc.subject | Humans | |
dc.subject | Molecular Docking Simulation | |
dc.subject | Plasmodium falciparum | |
dc.subject | Protein Conformation | |
dc.subject | Triazoles | |
dc.subject | Tubulin | |
dc.title | Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents | |
dc.type | Article | |
dc.rights.holder | Scopus | |
dc.identifier.bibliograpycitation | European Journal of Medicinal Chemistry. Vol 85, (2014), p.65-76 | |
dc.identifier.doi | 10.1016/j.ejmech.2014.07.087 | |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.